BOULDER, Colo., Jan. 29, 2013 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the second quarter of fiscal 2013 on Monday, February 4, 2013, and will hold a conference call on Tuesday, February 5, 2013 at 9:00 a.m. eastern time to discuss these results. Ron Squarer, Chief Executive Officer and Michael Carruthers, Chief Financial Officer will lead the call.
Conference Call Information
Date: | Tuesday, February 5, 2013 |
Time: | 9:00 a.m. eastern time |
Toll-Free: | (800) 447-0521 |
Toll: | (847) 413-3238 |
Pass Code: | 34113160 |
Webcast & Conference Call Slides: | |
http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-irhome | |
A replay of the call will be available as a webcast on www.arraybiopharma.com | |
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company with significant progress toward generating data to support our upcoming Phase 3 / pivotal trial decisions. Array-invented MEK162 will be tested in a Phase 3 trial in NRAS melanoma in the next several months as well as BRAF mutant melanoma later in 2013 (with Novartis). Four other Array invented drugs are also approaching Phase 3 decisions by the end of calendar year 2013. These include Array's wholly owned drugs, ARRY-614 and ARRY-520, and two additional partnered programs, selumetinib (with AstraZeneca) and danoprevir (with InterMune / Roche). For more information on Array, please go to www.arraybiopharma.com.
SOURCE Array BioPharma Inc.
